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KEY POINTS
 Extracorporeal photopheresis induces an immune response to mycosis fungoides (MF)/Se´zary
syndrome (SS).
 Extracorporeal photopheresis alone or in combination with other immunostimulatory agents leads
to a response rate ranging from 40% to 60% in patients with various stages of MF/SS.
 Extracorporeal photopheresis is a safe procedure with few side effects and no induction of
immunosuppression.INTRODUCTION
Cutaneous T-cell lymphoma (CTCL) is a broad
term describing cancers of the T cell whereby
the skin is the primary organ of involvement.
Although the disease was first recognized in
1806 by Alibert,1 it was not until the 1970s when in-
vestigators discovered the T-cell origin of this ma-
lignancy.2 Extracorporeal photopheresis (ECP) or
photopheresis is one of many treatment modalities
to treat the cutaneous T-cell lymphomas. It is
unique among those treatment modalities, how-
ever, in that it is the only treatment, aside from allo-
geneic stem cell transplantation, that specifically
induces an immune reaction directed against the
malignant T cell.
ECP is an apheresis procedure whereby a
leukocyte-enriched fraction of blood spiked with
8-methoxypsoralen (8-MOP) is exposed to a UV-
A light source and then returned to patients. ECPDisclosure: No conflicts of interest.
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under the CC BY-NC-ND license (http://creativecommons.is similar to the psoralen followed by UV-A expo-
sure (PUVA) form of phototherapy in that both
take advantage of the photoactivated drug
8-MOP and are classified as photochemothera-
pies. In 1988, the US Food and Drug Administra-
tion (FDA) approved the use of a new medical
device for the treatment of CTCL. The UVAR in-
strument (Therakos Inc, Exton, PA) combined, for
the first time, leukapheresis with a modified photo-
therapy chamber.
HISTORICAL ASPECTS
In 1921, J.F. Heymans3 first published the concept
of treating blood by exposing it to physical agents,
such as cold, heat, or radiation, as it flows through
an extracorporeal shunt. A better understanding of
lymphocyte function and life span emerged in the
late 1950s leading to the development of proce-
dures to deplete the body of lymphocytes to studyMedicine, 701 Thompson Ln, Ste 26300, Nashville, TN
blished by Elsevier Inc. This is an open access article
org/licenses/by-nc-nd/4.0/).
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In the early 1960s, Eugene Cronkite, MD, while at
the Brookhaven National Laboratory in Upton,
New York, developed an extracorporeal system
using a venovenous shunt to expose whole blood
to gamma rays generated by a 60cobalt irradiator.5
This modality, called extracorporeal irradiation of
the blood (ECIB), was based on the difference be-
tween the radiosensitivity of lymphocytes and the
radioresistance of erythrocytes.6 By 1970, at least
150 patients with acute and chronic leukemias
were treated with ECIB; but remissions were short
lived.7 Although most authorities thought only
gamma radiation could kill activated lymphocytes
and leukemic cells, a French team in the late
1960s led by J.L. Binet investigated the effects of
using UV radiation (UVR) produced by mercury
arc lamps.8 Their UVR ECIB system was tested
on lymphocyte function and ultimately in several
patients with chronic lymphocytic leukemia lead-
ing to transient clinical remission.9
In the mid-1970s, Barbara Gilchrest and col-
leagues10,11 at Massachusetts General Hospital
discovered that PUVA phototherapy was effective
in treating the early skin lesions of mycosis fun-
goides (MF), the most common subtype of
CTCL. At about the same time, Richard L. Edel-
son,12 MD, while at the National Cancer Institute,
worked with colleagues to treat several patients
with Se´zary syndrome (SS) using leukapheresis
to debulk the circulating tumor load of malignant
T cells.12 The question arose whether the malig-
nant circulating lymphocytes in SS would respond
to PUVA phototherapy if the energy could be
directed at blood cells. Initial experiments per-
formed in Edelson’s laboratory found evidence
that an anti-idiotypic response to disease-
specific T-cell receptors could be found after
exposing autoreactive T cells from rats to 8-MOP
and UV-A in an ex vivo system inspired by Cohen
and colleagues13–15 at the Weizmann Institute.
With the help of engineers at Therakos, Inc, a sub-
sidiary of Johnson and Johnson, Edelson16 de-
signed a device that could expose a fraction of
leukocyte-enriched blood, removed from patients
after they had taken psoralen, to UV-A light in an
extracorporeal system before returning the treated
blood products back to the patients. After a prom-
ising phase I clinical trial, a multicenter clinical trial
was performed from 1982 to 1986 testing the effi-
cacy of ECP after ingestion of 8-MOP in the man-
agement of refractory erythrodermic patients with
MF/SS. In 1987, the landmark report was pub-
lished that found a significant response in 27 of
37 patients treated with ECP.17
In 2000, the FDA approved a sterile liquid formu-
lation of 8-MOP to replace the oral formulation.The liquid formulation (UVADEX) is added directly
to the collection bag in the extracorporeal circuit,
thus avoiding the gastrointestinal intolerance and
unreliable blood levels of the oral formulation.15
The latest fourth-generation photopheresis instru-
ment, the CELLEX System (Therakos, Inc, Raritan,
NJ), was approved in 2009 by the FDA and com-
bines state-of-the-art cell collection, photoactiva-
tion, and reinfusion technologies in a single,
integrated, closed system.18MECHANISM OF ACTION
Despite the safe and effective use of ECP for more
than 25 years, the precise mechanism of action
continues to be explored. There is good evidence
that ECP induces an immune-mediated response
to the malignant T-cell clone.17 This is supported,
in part, by the clinical observation that, although
less than 10% of the total population of white
blood cells is treated during one ECP treatment,
there is often a larger reduction of malignant T cells
in the peripheral circulation.19 The proposed
mechanism of action involves the following pro-
cesses: (1) the induction of apoptosis of malignant
T cells, (2) the conversion of circulating monocytes
to immature dendritic cells (DCs), (3) the presenta-
tion of tumor-loaded DCs to cytotoxic T cells, and
(4) expansion of a population of cytotoxic T cells
against the malignant T-cell clone.
Because they lack nuclei, the radioresistance of
erythrocytes and platelets may be expected. How-
ever, the differences in the radiosensitivity of pe-
ripheral blood mononuclear cells (PBMCs) are
more difficult to explain. Why are lymphocytes
more radiosensitive than other peripheral blood
mononuclear cells?20,21 Also intriguing are the re-
sults of Spary and colleagues22 demonstrating
enhancement of the Th1 T-cell responses as a
result of synergy between lower doses of ionizing
radiation (0.6–2.4 Gy) and T-cell stimulation.
Further studies are needed that focuson the impact
of ECP (UV energy) on enhancement of Th1 T-cell
responses of normal T cells. ECP and PUVA induce
apoptosis inCD41 andCD81 lymphocytes but not
monocytes, and the apoptosis is likely attributed to
dysregulation in the expression of the apoptotic
genes Bcl-2 and Bax.23–26 But what about the sur-
viving malignant T cells exposed to UV-A energy
and psoralen? Studies using ionizing radiation
demonstrate alteration in the biology of surviving
tumor cells from patients with solid organ carci-
nomas, rendering them more susceptible to T
cell–mediated killing possibly via increased cell-
surface expression of calreticulin.27
It has been established that monocytes differen-
tiate to immature DCs in the presence of
ECP in the Treatment of CTCL 767interleukin (IL)-4 and granulocyte-macrophage
colony stimulating factor (GM-CSF).28 In 2001,
Berger and colleagues29 published their observa-
tion of the conversion of monocytes to immature
DCs during overnight incubation in gas-
permeable bags of ECP-treated leukocytes from
5 patients with refractory CTCL. Further observa-
tions confirmed that both the initial leukapheresis
step and subsequent passage through the narrow
plastic photoactivation plate initiated and contrib-
uted to the monocyte to immature dendritic cell
differentiation. Edelson proposed that the frequent
encounters of monocytes with the plastic surface
of the photoactivation plate activated the cells to
begin differentiation to immature DCs.30 The
adsorption of fibronectin on the photoactivation
plate may be a convincing candidate for influ-
encing monocyte biology during ECP and partici-
pating in the early events of monocyte-to-DC
conversion.31 Recently, Berger and colleagues32
demonstrated that ECP-derived DCs are matura-
tionally synchronized and show a reproducible
distinctive molecular signature, common to ECP-
processed monocytes from normal subjects and
those from patients.
There are 2 major subsets of DCs in human pe-
ripheral blood: myeloid (mDC) and plasmacytoid
(pDC).33 It is known that mDCs primarily polarize
naı¨ve T cells toward a Th1 phenotype, whereas
pDCs primarily result in a Th2/Treg phenotype.34
Recently, Shiue and colleagues35 found increased
mDC populations, increased mDC/pDC ratios,
and upregulation of HLA-DR expression on DCs
following ECP in two-thirds of patients with MF
and B1/B2 blood stage or SS. Their results sug-
gest that ECP treatment is associated with favor-
able mDC modulation.
Inducing a Th1 phenotype produces a cell-
mediated T-cell response capable of launching a
cytotoxic T-cell response against a malignant
clone. Clinical improvements after ECP in patients
with MF/SS are associated with a shift from Th2 to
IL-12/Th1 phenotype.36
Using an animal model of ECP, investigators
identified the induction of a CD81 T-cell response
against expanded clones of pathogenic T cells.14
Moor and Schmitt37 demonstrated increased syn-
thesis of class I major histocompatibility complex
molecules on the surface of a murine T-cell lym-
phoma line after exposure to UV-A and 8-MOP.
In addition, Berger and colleagues38 used mono-
clonal antibodies and magnetic bead technology
to demonstrate a tumor-specific cytolytic CD81
T-cell response to distinctive class I–associated
peptides on the surface of CTCL tumor cells in
blood samples from 4 ECP patients with advanced
CTCL. These data support the assertion that ECPexerts its immunologic effects by stimulating a
tumor-specific CD8 T-cell response triggered by
a population of tumor-loaded DCs after the ECP
procedure.
To summarize: In patients with MF/SS and sig-
nificant blood involvement, ECP treatment not
only induces apoptosis of malignant Th2/Treg
cells but also induces more mDCs, creates a
proinflammatory environment for DCs to activate,
and further stimulates Th1/cytotoxic T cells and
immune responses.35PHARMACOKINETICS
8-MOPormethoxsalen is a furocoumarin with pho-
toactivating properties. Methoxsalen, on photoac-
tivation, conjugates and forms covalent bondswith
DNA, which lead to the formation of both mono-
functional (addition to a single strand of DNA) and
bifunctional (crosslinking of psoralen to both
strands ofDNA) adducts.39 Reactionswith proteins
have also been described. The formation of photo-
adducts results in inhibition of DNA synthesis, cell
division, and epidermal turnover.39 Liquid methox-
salen (UVADEX 20 mcg/mL) is administered in a
dose of 0.017 mL per 1 mL of pheresed leukocyte
volume.18 The total dose of methoxsalen delivered
inUVADEX is substantially less than (approximately
200 times) that used with oral administration. More
than 80% of blood samples collected 30 minutes
after reinfusion of the photoactivated cells hadme-
thoxsalen levels less than the detection limits of the
assay (<10 ng/mL).40
Just and colleagues41 explored the trafficking of
the treated leukocytes following ECP using radio-
actively labeled leucocytes and monitoring with
whole-body scintigraphy. Comparison of distribu-
tion patterns showed that PBMCs and neutrophils
have different kinetic patterns after intravenous
reinjection. The most prominent difference was
immediate retention of PBMCs but not of neutro-
phils in the lungs corresponding to a signal 3 times
more intense. After 24 hours, more than 80% of
both cell populations could be detected in the liver
and spleen.TYPICAL REGIMEN
For patients with MF/SS, the typical ECP regimen
is one treatment on 2 consecutive days every
4 weeks. Since FDA approval of ECP in 1988, there
has been minor variability in the 2-day cycle every
4 weeks in the treatment of MF/SS. Duvic and
colleagues42 found no increased response rate us-
ing an accelerated regimen of one 2-day cycle
every 2 weeks to treat a small cohort of patients
with MF/SS. More recently, Siakantaris and
Zic768colleagues43 from Greece published their retro-
spective experience (N5 18) using an accelerated
treatment schedule of one cycle of ECP every
week for 1 month, followed by 1 cycle of ECP
every 2 weeks for 2 months, and then one cycle
of ECP every month. The overall response rate of
61% compares quite favorably with previously
published response rates of patients with MF/SS
treated with ECP combined with other systemic
therapies.
The European Dermatology Forum’s guidelines
on the useofECPpublished in January 2014 recom-
mends the following ECP schedule for the treatment
ofMF/SS:1cycleevery2weeks for the first3months
then once monthly or every 3 weeks.44 The investi-
gators note, however, that there is no clear optimal
therapy; other published guidelines, including the
UK consensus statement on the use of ECP,45
have recommended 1 cycle every 2 to 4 weeks fol-
lowed by tapering after maximum response.44
Each ECP procedure varies between 2 and 3
hours in length based on several factors, including
venous access, blood flow, hemoglobin concentra-
tions, and technical issues. Most centers achieve
peripheral access using one 16-gauge or 18-gauge
needle inserted into the antecubital vein thoughcen-
tral venous catheters, or specialized subcutaneous
ports (eg, Vortex AngioDynamics, Latham, NY) that
allow for rapid reverse flow during the blood collec-
tion phase of the procedure may also be used.46RESPONSE TO THERAPY
The efficacy of ECP has been reported in more
than 500 patients worldwide. Most of these reports
have been small to medium size case series. There
are no randomized controlled clinical trials demon-
strating the efficacy of photopheresis as mono-
therapy in the treatment of MF/SS. Despite this,
several national and international organizations
have listed photopheresis as first-, second-, or
third-line therapy for various stages of MF/SS.
The clinical data support the use of ECP to treat
patients with erythrodermic MF (T4N0-3M0B1) with
at least some atypical circulating lymphocytes or
SS (T4N0-3M0B2), which requires significant blood
involvement for diagnosis. The clinical data do not
support the use of ECP to treat patients with tumor
stage MF. There is some clinical data to support
the use of photopheresis to treat early stage pa-
tients with MF, especially those that have at least
some atypical circulating lymphocytes.EARLY STAGE MYCOSIS FUNGOIDES
After ECP was FDA approved in 1988, several re-
ports emerged of patients with early stage MFresponding to ECP often combined with other
treatment modalities.47–50 Zic and colleagues48,49
at Vanderbilt reported preliminary and long-term
follow-up data on a cohort of 20 refractory patients
with MF/SS treated with ECP and adjunctive
therapies. This cohort included 14 treatment-
refractory patients with early stage disease (T2).
Nine of 14 (64%) achieved an objective response
(OR) in the skin (greater than 50% clearing of
skin lesions) with 4 complete responses (CRs).
For the 7 patients who at some point in their treat-
ment achieved a CR, the median time to clearing
was 11 months. For the 7 patients weaned from
ECP, the mean relapse-free interval was approxi-
mately 45 months (range, 20–64 months, 2 re-
lapses). Another important observation was that
patients who responded within 6 to 8 months after
starting ECP maintained their response over
time.49
In 2004, Child and colleagues51 published the
results of a randomized crossover study
comparing PUVA and ECP in the treatment of 20
patients with plaque stage (T2) MF who had a
detectable peripheral blood T-cell clone. Eight pa-
tients completed the study. Although PUVA was
more effective than ECP in improving skin scores,
neither treatment modality cleared malignant T
cells from the peripheral blood.
In a retrospective analysis of patients treated
with ECP combined with adjuvant therapies, Sia-
kantaris and colleagues43 from Greece reported a
response rate of 40% (2 of 5) in patients with early
stage MF as compared with a response rate of
62% (9 of 13) in patients with advanced MF/SS.
Recently, a prospective, open-label, single-arm,
multicenter, investigator-initiated pilot study was
completed to assess the response to ECP in pa-
tients with early stage MF (stages IA–IIA).52 The
UVAR XTS Photopheresis System (Therakos, Inc
Raritan, NJ) was used to administer ECP for 2
consecutive days oncemonthly for 12months. Pa-
tients who did not respond after 6 months of ECP
were treated adjunctively with oral bexarotene
(150 mg/m2) alone or combined with interferon
(IFN) alfa (1–3 million units 3 times per week). Pa-
tients with stage IA disease were only enrolled if
they showed evidence of minor blood abnormality
by flow cytometry assessment (B1). The primary
end point was a skin involvement response as-
sessed monthly by using the modified severity
weighted assessment tool (mSWAT) assessment
tool (partial response [PR] >50% improvement in
mSWAT). A total of 19 patients with early stage
MF (IA 5 3, IB 5 14, IIA 5 2) were enrolled. Eight
of the 12 patients who were treated with ECP
monotherapy responded (67%, 2 CR), and 4 of
the 7 patients who received combination therapy
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for the entire cohort (12 of 19) was 63.1%. Howev-
er, if the 7 patients requiring combination therapy
are considered ECP treatment failures, then the
overall response rate for ECP alone was 42% (8
of 19). The median time to response was 4 months
(3–8months), and themedian duration of response
was 6.5 months (1–48 months). Also, quality-of-life
measurements indicated an improvement in
emotional scores over time.52
Current National Comprehensive Cancer
Network (NCCN) guidelines for non-Hodgkin lym-
phoma (NHL) (Version 5.2014) do not recommend
ECP as primary treatment in early stage MF (IA, IB,
IIA). However, in patients with stage IA, IB, and IIA
disease and B1 blood involvement or those with
treatment refractory disease, ECP is listed as a
systemic treatment option along with retinoids,
IFNs, histone deacetylase inhibitors, and metho-
trexate.53 The European Dermatology Forum pub-
lished guidelines on the use of ECP in January
2014. The consensus decision was that ECP
should only be considered in patients with early
stage MF for clinical trial purposes as a variety of
other safe, effective, and easily accessible treat-
ment options are available for use at these
stages.44TUMOR STAGE MYCOSIS FUNGOIDES
ECP should not be considered a primary treatment
option in patients with tumor stage MF (stage IIB).
In 15 patients extracted from the literature with
skin stage T3 (tumor stage), no patient responded
to photopheresis.49,50,54,55 One retrospective
study examined the use of ECP or chemotherapy
as a maintenance adjuvant treatment regimen in
patients with tumor stage MF (N 5 41) or erythro-
dermic MF/SS (N 5 21) who had achieved a CR
from total skin electron beam radiotherapy
(TSEB).56 The difference between overall survival
for those who received ECP (100% at 3 years)
versus those who received no adjuvant therapy
(50% at 3 years) approached statistical signifi-
cance (P<.06), whereas significant survival benefit
from the addition of chemotherapy (75%at 3 years)
for TSEB CRs was not observed. Neither adjuvant
therapy provided benefit with respect to relapse-
free survival after TSEB.56ERYTHRODERMIC MYCOSIS FUNGOIDES AND
SE´ZARY SYNDROME
Erythrodermic CTCL may be divided into erythro-
dermic MF (stage III, T4N0-2M0B0-1) and SS (stage
IVA1 or 2, T4N0-3M0B2). Although there is consider-
able variability in the presentation and prognosis ofpatients with erythrodermic MF/SS, photopheresis
is considered the first-line treatment by most ex-
perts. The publication of the landmark article in
1987 by Edelson and colleagues17 established
the safety and efficacy of ECP in 22 of 29 erythro-
dermic patients with MF/SS. Since then, the re-
sponses of more than 518 ECP-treated patients
with erythrodermic MF/SS have been published
and summarized with a wide range of response
rates from 33% to 74%.44,57 Many of these pa-
tients were treated with photopheresis in combi-
nation with other therapies. In addition, none of
the patients were part of prospective randomized
controlled clinical trials.
The United States Cutaneous Lymphoma Con-
sortium (USCLC) recently published guidelines
for the treatment of SS.58 In this review 118 pa-
tients with SS treated with ECP as monotherapy
were extracted from the literature based on clearly
defined criteria and an overall response rate
defined as at least 50% clearing. Of these 118 pa-
tients, 28 (24%) responded to ECP monotherapy
and 11 patients achieved a CR (9%). Higher
response rates were seen in patients who received
ECP in combination with other therapies (Fig. 1).
ECP was recommended by the USCLC as one of
the primary (category A) systemic monotherapies
for the treatment of SS (II-2 evidence:1 prospec-
tive, well-designed cohort or case-controlled
study, preferably >1 center or research group).
Others in this category included IFN alfa, bexaro-
tene, low-dose methotrexate, and denileukin difti-
tox plus corticosteroids.58
BasedonECPdata from1987 to2001, theBritish
Photodermatology Group and United Kingdom
Skin Lymphoma Group published their report in
2006 on evidence-based practice of ECP.59 The in-
vestigators concluded that there was fair evidence
of clinical benefit in erythrodermicMF/SS fromECP
(B level recommendation [A toE], II-i evidence [non-
randomized controlled trials]).
Based on category 2A evidence (lower-level ev-
idence and uniform NCCN consensus that the
intervention is appropriate), current NCCN guide-
lines for NHL (version 5.2014) do recommend
ECP as one of the primary treatments for SS and
erythrodermic MF with B1 blood stage but not
for patients with erythrodermic MF with no evi-
dence of blood involvement (B0).53 In contrast,
the European Dermatology Forum’s guidelines
recommend ECP as first-line therapy for all pa-
tients with T4 skin stage regardless of blood and
lymph node involvement and patients with T1/T2
skin stage with B2 blood involvement according
to the revised International Society for Cutaneous
Lymphomas (ISCL)/European Organization of
Research and Treatment of Cancer (EORTC)
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Fig. 1. Estimated pooled response rates for patients with SS to ECP monotherapy, ECP 1 IFN alfa or gamma, and
ECP 1 IFN 1 bexarotene capsules (Bex). N 5 number of patients extracted from the literature with a clear defi-
nition of SS and an overall response rate defined as 50% or greater clearing of skin. (Data from Olsen EA, Rook
AH, Zic J, et al. Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommen-
dations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol
2011;64(2):352–404.)
Zic770staging.60 The American Society for Apheresis
also categorized ECP as an accepted first-line
therapy for erythrodermic MF/SS as a primary
stand-alone treatment or in conjunction with other
modes of treatment.61EXTRACORPOREAL PHOTOPHERESIS AND
ADJUNCTIVE THERAPIES
Most patients with MF/SS treated with ECP
receive adjunctive therapies, especially IFN alfa
and bexarotene capsules. There is evidence to
support higher response rates when ECP is com-
bined with adjunctive therapies. In one report,
ECP monotherapy showed a 40% response rate
in patients with stage III/IV MF/SS in contrast to
a 57% response rate in those treated with a com-
bination of ECP plus IFN alfa, bexarotene, or GM-
CSF.62 In a retrospective review of 98 patients with
SS treated with ECP (>3 months) and 1 or more
systemic immunostimulatory agents (IFN gamma,
IFN alfa, GM-CSF, systemic retinoids), Raphael
and colleagues63 at the University of Pennsylvania
reported a significant improvement in 73 patients
(75%) with 29 CRs (30%).
There are retrospective and small cohort data to
support the combination of photopheresis and IFN
in the treatment of erythrodermic CTCL. In the
USCLC review of SS in which all patients so re-
ported had to meet the criteria of T4B2 stagingand an overall response rate defined as at least
50% clearing of disease, 10 of 22 patients treated
with ECP and IFN alfa (45.4%) responded,
including 4 patients who achieved a CR (18.2%)
(see Fig. 1).58 In the only published prospective
randomized trial of IFN versus IFN and ECP, 20 pa-
tients with MF/SS stages IA to IVB were treated
with IFN 3 to 18 million units (MU) daily intramus-
cularly versus same-dosing IFN plus ECP 2 days
per month. Two of the 9 patients (22%) assigned
to the combination arm had an OR versus 4 of
the 11 patients (36%) assigned to the IFN alone
arm, including one CR.64 Thus there was no
advantage to adding ECP to IFN alone in this small
study.
The combination of ECP, IFN alfa/gamma, and
bexarotene capsules may lead to the highest
response rates in patients with SS. In the USCLC
review of the 34 patients with SS treated with
ECP, IFN, and bexarotene, 30 of 34 (88.2%) re-
sponded to the combined therapy, including 11
patients with a CR (32.4%) (see Fig. 1).58 Bexaro-
tene dosages ranged from 75 mg to 450 mg by
mouth per day. IFN alfa dosages ranged from 1.5
MU to 6 MU subcutaneous injections 3 to 5 times
weekly. IFN gamma dosages ranged from 40 mcg
to 100 mcg subcutaneous injections 3 to 5 times
weekly.58
In contrast to these pooled results, Polansky
and colleagues65 at the M.D. Anderson Cancer
ECP in the Treatment of CTCL 771Center recently reported the results of 18 of 217
patients with SS who had achieved long-term CR
of greater than 1 year: 3 CRs were achieved with
combined immunomodulatory therapy (ECP, IFN
alfa, and/or retinoids), 13 CRs were achieved after
allogeneic stem cell transplantation, one CR with
alemtuzumab, and one CR with mogamulizumab.PREDICTORS OF RESPONSE
In a small cohort of 21 patients with MF/SS treated
with ECP as monotherapy for at least 6 months,
the following baseline blood parameters were asso-
ciated with a favorable clinical response: lower per-
centage of Se´zary cells (32% vs 54% lymphocytes)
and a higher absolute eosinophil count (388/mm3 vs
87/mm3). Comparison of cytokines, gene tran-
scripts, and other laboratory measures of disease
did not correlate with the subsequent clinical
response.66 In a more recent analysis of microRNA
(miR) levels on a subset of this cohort (n 5 13),
McGirt and colleagues67 discovered that an early in-
crease of PBMCmiR-191,miR-223, andmiR-342 at
3months into ECPmonotherapy predicted a clinical
response to ECP at 6 and 12 months.
In a large cohort of patients (n 5 98) with SS
treated with ECP and immunostimulatory agents,
Raphael and colleagues63 found the following
baseline differences in the CR group as compared
with the nonresponse group: lower CD4/CD8 ratio
(13.2 vs 44.2), lower median percentage of CD41/
CD26 cells (27.4% vs 57.2%), lower median per-
centage of CD41/CD7 cells (20.0% vs 41.3%),
and higher median monocyte percentage (9.5%
vs 7.3%). There were no differences between the
group with PR when compared with the nonre-
sponse group.
Other factors that have been reported to predict
response to ECP have been recently summa-
rized.57,68 They include relatively low tumor load
of malignant T cells in the blood, lymph nodes,
and skin; peripheral blood involvement; relatively
intact immune system; erythroderma; and plaques
covering less than 10% to 15% of the total skin
surface68 (Table 1).SURVIVAL
The impact of ECP alone or ECP in combination
with other therapies on the survival of patients
with erythrodermicMF/SS remains to be confirmed
with a prospective study. A follow-up analysis of
the original cohort of Edelson and colleagues69
was published in 1992 showing that the median
survival for patients who received ECP was
60 months. Gottlieb and colleagues47 and Zic and
colleagues49 reported similar median survivals intheir respective cohorts of ECP-treated patients
with MF/SS. In 2012, Knobler and colleagues70
used ISCL/EORTCcriteria to reevaluate the original
cohort of 39 patients in the 1987 pivotal trial by
Edelson and colleagues17 with a median follow-
up of 71.6months in this cohort; themedian overall
survival for a subgroup of 26 patients with erythro-
derma was 76.9 months from diagnosis.
Fraser-Andrews and colleagues71 published a
retrospective historical control study comparing
the survival of a cohort of 44 patients with SS
separated into 3 groups: ECP treated 1991 to
1996 (n 5 29, median survival 39 months), no
ECP treatment 1991 to 1996 (n 5 8, median sur-
vival 22 months), and no ECP treatment before
1991 (n 5 7, median survival 26.5 months). In
contrast to the previously published survival data
at that time, this study showed no statistically sig-
nificant difference between the groups and did not
support the contention that ECP prolongs survival
in patients with SS. In a letter to the editor, Stevens
and colleagues72 argued that this study had low
statistical power and an inadequate treatment
regimen for proper comparison.ADVERSE EFFECTS
ECP is well tolerated with rare grade III-IV systemic
toxicities reported in the literature and no reports of
immunosuppression. Ina recent seriesof 51patients
with erythrodermic MF/SS treated with ECP, the
following adverse effects were reported using the
National Cancer Institute Common Toxicity Criteria
system: transient grade I hypotension (12%), grade
I-II anemia (6%), hypokalemia (4%), and 1 urticarial
eruption interpreted as a drug reaction to either 8-
MOP or heparin.57 Discomfort andmild hematomas
at venipuncture sites are not uncommon and can be
relieved with pressure bandages and ice com-
presses.17 To avoid catheter-related infections,
intermittent peripheral venous access is preferred
over indwelling catheters because of the high rate
of Staphylococcus aureus colonization on the skin
in patients with erythrodermic MF/SS. Transient
low-grade fever and increased erythroderma have
been observed in some patients within 6 to 8 hours
of reinfusion of the photoactivated leukocyte-
enrichedblood.18Nauseawasacommonsideeffect
to the oral formulation of 8-MOP but has now been
eliminatedwith the introduction of the liquid formula-
tion directly injected into the collection bag.15 A sin-
gle caseof grade III anemiawas reported in a patient
with SS undergoing treatment with bexarotene and
ECP caused by undiagnosed cold agglutinin dis-
ease, which was suspected when agglutinated
bloodwas noted in the centrifuge bowl of the photo-
pheresis device.73
Table 1
Baseline predictors of response to photopheresis
Low Tumor Load of Malignant T Cells
Skin Erythrodermaa Quaglino et al,57 2013; Knobler
et al,44 2014
Plaques <10%–15% total skin surface Atta et al,68 2012; Knobler et al,44
2014
Blood Lower percentage of elevated
circulating Se´zary cells
Heald et al,69 1992; Raphael et al,63
2011; McGirt et al,66 2010
Lower CD4/CD8 ratio <10–15 Heald et al,69 1992; Knobler et al,74
2002; Raphael et al,63 2011;
Quaglino et al,57 2013
Lower % CD41CD7 <30% Stevens et al,75 2002; Raphael et al,63
2011
Lower % CD41CD26 <30% Raphael et al,63 2011
Normal LDH levels Knobler et al,74 2002; Quaglino
et al,57 2013
B0 or B1 blood stage Quaglino et al,57 2013
Lymphocyte count <20,000/ml Atta et al,68 2012
Lymph nodes Lack of bulky adenopathy Atta et al,68 2012
Visceral organs Lack of visceral organ involvement Atta et al,68 2012
Peripheral Blood
Involvement
B1 blood stage >B2 blood stage60 Quaglino et al,57 2013; Evans et al,76
2001; Atta et al,68 2012
Presence of a discrete number of
Se´zary cells (10%–20%
mononuclear cells)
Knobler et al,44 2014
Relatively Intact
Immune System
Higher % monocytes >9% Raphael et al,63 2011
Increased eosinophil count >300/mm3 McGirt et al,66 2010
No previous intense chemotherapy Zic,18 2012; Atta et al,68 2012
Short disease duration before ECP
(<2 y from diagnosis)
Atta et al,68 2012; Quaglino et al,57
2013
[ NK cell count at 6 mo into ECP
therapy
Prinz et al,77 1995; Quaglino et al,57
2013
Near-normal NK cell activity Knobler et al,44 2014
Normal CD31CD81 cell count
>200/mm3
Quaglino et al,57 2013
Other Monitored Factors
PBMC miR levels [ miR-191, [ miR-223, [ miR-342 at
3 mo into ECP monotherapy
McGirt et al,67 2014
Soluble interleukin-2
receptor
YsIL-2R at 6 mo into ECP Rao et al,78 2006
Neopterin Y Neopterin at 6 mo into ECP Rao et al,78 2006
Beta2-microglobulin Y Beta2-microglobulin at 6 mo into
ECP
Rao et al,78 2006
Response at 5–6 mo
of ECP
Predicts durable response and long-
term survival
Stevens et al,75 2002; Zic et al,49 1996
Abbreviations: LDH, lactate dehydrogenase; NK, natural killer; sIL-2R, soluble interleukin-2 receptor.
a Patients with erythrodermic MF/SS often show fewer malignant T cells in skin biopsies than T3 and T2 skin stages.
Zic772PEARLS TO HELP THE MANAGEMENT OF
PATIENTS WITH MYCOSIS FUNGOIDES/
SE´ZARY SYNDROME BEING TREATED WITH
EXTRACORPOREAL PHOTOPHERESIS
As with any therapy, patient selection is important.
It is important to set patient expectations at thebeginning of ECP treatment. Patients rarely obtain
a rapid response to ECP; they should, therefore,
be told that it may take at least 6 to 8 months of
treatment to see a significant response. Patients
who tend to respond best to ECP are those with
erythrodermic variants (T4 MF or SS), including
patients that one suspects are evolving into SS.
ECP in the Treatment of CTCL 773Patients who have many predictive factors for
response can initiate ECP as monotherapy. If pa-
tients do not show a significant response by 6 to
8 months of ECP (stable disease), then the author
recommends adding adjunctive therapies (IFN,
bexarotene) or switching to an alternative therapy.
If patients show progressive disease, then the
author would add or switch therapies sooner. In
contrast, patients with fewer predictive factors
for response, especially those with SS and lymph-
adenopathy, should be treated up front with com-
bination immunotherapy (ECP, IFN alfa or gamma,
bexarotene). If patients do not show a significant
response by 6 to 8 months of ECP, the author rec-
ommends stopping ECP and switching to an alter-
native systemic therapy.
Venous access can be a challenge for heavily
pretreated patients and older patients. To increase
the caliber of the antecubital veins, the author rec-
ommends instructing patients to squeeze rubber
balls with both hands as a daily exercise.SUMMARY
In the setting of MF/SS, photopheresis leads to an
expansion of peripheral blood DC populations and
an enhanced TH1 immune response. ECP is a first-
line therapy for erythrodermic MF/SS based on the
excellent side effect profile and moderate efficacy
in the treatment of patients with T4 (erythroderma)
skin stage. Patients with erythrodermic MF/SS are
most likely to respond to ECP when they have a
measurable but low blood tumor burden. The
addition of adjunctive immunostimulatory agents
seems to increase the response to ECP. There
may be a role for the treatment of refractory early
stage MF with ECP, though data are limited.
Further studies are needed not only to clarify the
mechanism of action of ECP to better optimize
therapy but also to maximize the response for pa-
tients with advanced MF/SS.REFERENCES
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